{
    "nctId": "NCT00066586",
    "briefTitle": "Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer",
    "officialTitle": "A Randomized Study Of The Effect Of Exemestane (Aromasin) Versus Placebo On Breast Density In Postmenopausal Women At Increased Risk For Development Of Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 98,
    "primaryOutcomeMeasure": "Change in breast density as measured by Boyd Scale at 1 year",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Radiologically confirmed density occupying at least 25% of the breast tissue on baseline mammogram\\*\n\n  * Grade 2, 3, 4, 5, or 6 (Boyd classification)\n\n    * Participants with different grades between the 2 breasts should be classified according to a higher grade NOTE: \\*Performed within 6 months before study entry\n* Bone mineral density T-score of either posterior-anterior spine or hip (femoral neck) must be no greater than 2.0 standard deviations below the mean value of peak bone mass in young normal women as determined by DEXA scan within the past 6 months\n* No concurrent breast cancer\n* No prior invasive breast cancer or ductal carcinoma in situ\n* No breast implants\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* Postmenopausal\n\nSex\n\n* Female\n\nMenopausal status\n\n* Postmenopausal, defined as 1 of the following:\n\n  * Over 50 years of age with no spontaneous menses for at least 1 year\n  * 50 years of age and under with no menses (e.g., spontaneous or secondary to hysterectomy) within the past year AND a follicle-stimulating hormone level within institution postmenopausal range\n  * Bilateral oophorectomy\n\nPerformance status\n\n* Not specified\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* Not specified\n\nRenal\n\n* Not specified\n\nCardiovascular\n\n* No cardiovascular disease\n* No history of myocardial infarction\n* No history of stroke\n* No uncontrolled high blood pressure\n\nOther\n\n* No uncontrolled metabolic or endocrine disease\n* No malabsorption syndrome\n* No known hypersensitivity to exemestane or its excipients\n* No other malignancy within the past 5 years except curatively treated squamous cell or basal cell skin cancer or carcinoma in situ of the cervix\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* No prior immunotherapy\n* No concurrent immunotherapy\n\nChemotherapy\n\n* No prior chemotherapy\n* No concurrent chemotherapy\n\nEndocrine therapy\n\n* More than 3 months since prior exogenous estrogen and/or progesterone/progestin therapy\n* More than 6 months since prior selective estrogen-receptor modulators (e.g., tamoxifen, toremifene, or raloxifene)\n* No concurrent selective estrogen-receptor modulators (e.g., tamoxifen, toremifene, or raloxifene)\n* No concurrent steroids\n* Vaginal estrogens allowed (e.g., Estring\u00ae or Vagifem\u00ae)\n\n  * No concurrent compounded creams\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* Not specified\n\nOther\n\n* More than 4 weeks since prior investigational agents\n* No other concurrent medications that would preclude study endpoints\n* No concurrent over-the-counter products or supplements considered to have an estrogenic effect, including any of the following:\n\n  * Ginseng\n  * Ginkgo biloba\n  * Black cohosh\n  * Dong quai\n  * Fortified soy supplements (e.g., phytoestrogen preparations)",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}